Corvus Pharmaceuticals
Prix: 11.93Entreprise et modèle économique
Corvus Pharmaceuticals is a healthcare company focused on developing immuno-oncology therapies for cancer treatment. Its core products include investigational drugs targeting specific cancer pathways, with a primary emphasis on enhancing the immune response against tumors. The company operates in the biotechnology segment, primarily generating revenue through research and development activities and potential future product sales.
Profil d’investissement
The investment profile of Corvus Pharmaceuticals is more aligned with growth investors, given its focus on developing innovative therapies in a high-risk sector. The lack of dividends and the company's current financial performance suggest a higher risk profile, making it less suitable for conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility for potential future gains.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -0.55 Risque
- Surprise BPA
- -7.1% moins bon que prévu
- Volatilité 20 j
- 4.7% stable
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-03 02:37 | Conserver | Vendre | scenario_deterioration |
| 2026-06-01 02:35 | Vendre | Conserver | Weak fundamentals and negative momentum signal high risk. |
| 2026-05-16 02:54 | Conserver | Vendre | scenario_deterioration |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-04-17 08:42 | Goldman Sachs | Mettre à jour | — → 40 | 15.04 |
| 2026-01-29 11:45 | Mizuho Securities | Objectif relevé | 20 → 30 | 20.54 |
| 2026-01-22 17:28 | Jefferies | Objectif relevé | 13 → 42 | 25.8 |
Rien pour le moment